MedPath

Effect of Empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes patients with heart failure with reduced ejection fractio

Phase 3
Conditions
Heart failure.
Heart failure, unspecified
I50.9
Registration Number
IRCT20211219053450N1
Lead Sponsor
Ahvaz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
112
Inclusion Criteria

Patients with type 2 diabetes mellitus (HbA1C= 6.5%) or pre-diabetes (HbA1c between 5.7% to 6.4%) and ischemic heart failure with reduced fractional ejection (LVEF = 40%)
over 18 years old
Functional NYHA Class II to IV
Patient consent for participation in research

Exclusion Criteria

Type 1 diabetes; Severe liver failure; eGFR History of diabetic ketoacidosis;
Existence of any malignancy and cancer;
Lack of adherence to the treatment regimen.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
eft ventricular volumes. Timepoint: before and 6 months after intervention. Method of measurement: Echocardiographic parameters.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath